Actinium Pharmaceuticals, Inc.

Manufacturer/Supplier in New York, New York

Actinium Pharmaceuticals, Inc. ( (NYSE MKT: ATNM) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.


Certifications, Standards and Eco-Labels

Actinium Pharmaceuticals, Inc. has obtained the following Certifications, Standards and Eco-Labels

Listing Categories



757 3rd Avenue, 21st Floor
New York, New York
USA 10017
(646) 459-4201

See more